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White and brown adipose tissues are hypervascularized and the adipose vasculature displays phenotypic
and functional plasticity to coordinate with metabolic demands of adipocytes. Blood vessels not only supply
nutrients and oxygen to nourish adipocytes, they also serve as a cellular reservoir to provide adipose precur-
sor and stem cells that control adipose tissue mass and function. Multiple signaling molecules modulate the
complex interplay between the vascular system and the adipocytes. Understanding fundamental mecha-
nisms by which angiogenesis and vasculatures modulate adipocyte functions may provide new therapeutic
options for treatment of obesity and metabolic disorders by targeting the adipose vasculature.Introduction
Forty-two years ago, Dr. Judah Folkman proposed the concept
of antiangiogenic therapy based on his observations in exper-
imental tumor models (Folkman, 1971). Today, Folkman’s
concept has successfully been translated into the development
of antiangiogenic drugs for the treatment of cancer and
ophthalmological diseases in human patients (Folkman,
2007). Would the same antiangiogenic concept work for treat-
ment of obesity and its related disorders? The definite answer
to this question relies on understanding the fundamental mech-
anisms that underlie vascular modulation of adipose tissue
functions.
Similar to tumor tissues, adipose tissues are highly vascular-
ized; brown adipose tissue (BAT) is one of the most vascular-
ized tissues in the body (Bra˚kenhielm and Cao, 2008; Cao,
2007, 2010). Throughout adulthood, white adipose tissue
(WAT) constantly undergoes expansion or shrinkage depending
on energy consumption and the metabolic demand of the host.
Alterations of adipose tissue mass and functions coordinately
necessitate angiogenesis or vascular regression, which are
controlled by various cell-type-derived growth factors, cyto-
kines, and adipokines (Cao, 2007). Hypervascularization in
BAT and WAT also implies the existence of an intimate interplay
between vascular and adipose compartments. In support of
this view, abundant recent data show that cells located in the
vessel wall, a significant component in the adipose microenvi-
ronment, provide precursor cells that ultimately differentiate
into preadipocytes and adipocytes (Gupta et al., 2012; Tang
et al., 2008).
Understanding vascular functions and the intimate
interplay between vascular cells and adipocytes may provide
an outstanding opportunity for therapeutic intervention for
obesity and its related metabolic diseases by targeting
the vascular compartment. However, targeting vasculature-
based therapeutic approaches for the treatment of obesity
currently remain hypothetical and have not been tested in
human subjects.478 Cell Metabolism 18, October 1, 2013 ª2013 Elsevier Inc.Cell-Type Switch between Vessel Walls and Adipocytes
A recent study demonstrates that white-fat progenitors reside in
the mural cell compartment of the adipose vessel wall (Tang
et al., 2008) (Figure 1). Furthermore, these specialized pericytes
and smooth-muscle-like cells express PPAR-g stem cell antigen
1(Scal1), CD34, a-smooth muscle actin (a-SMA), platelet-
derived growth factor receptor b (PDGFR-b), and NG2, which
distinguishes this adipose-tissue-derived pericyte population
from other cells. Similarly, genetic labeling of Zfp423, a multi-
zinc-finger transcriptional regulator, demonstrates a perivascu-
lar origin of preadipocytes, and this transcription factor is both
necessary and sufficient for the development of a common pre-
cursor of white and brown adipocytes (Gupta et al., 2012).
Vascular endothelial cells also retain multipotent stem cell-like
features and can, under the influence of transforming growth
factor b2 (TGF-b2), differentiate into adipocytes, as well as other
cell types (Medici et al., 2010). This view is supported by the fact
that some mural cells and a very small subset of CD31+ capillary
endothelial cells express Zfp423, a gene controlling preadipo-
cyte determination, raising the possibility of the vascular origin
of preadipocytes (Gupta et al., 2012) (Figure 1). The VE-cadherin
promoter-driven lineage-tracing experiments provide an inde-
pendent line of evidence that both pericytes and murine endo-
thelial cells can differentiate into preadipocytes and adipocytes
(Tran et al., 2012). Taken together, these findings support the
concept of endothelial and perivascular origins of preadipo-
cytes, suggesting that adipogenesis, angiogenesis, and vascular
remodeling are tightly and coordinately regulated.
Similar to vascular cells, mature white adipocytes also exhibit
multilineage potential to differentiate into multiple mesenchymal
lineages including bone, cartilage, cardiomyocytes, and skeletal
muscles (Jumabay et al., 2010) (Figure 1). In response to bone
morphogenetic proteins 4 and 9 (BMP4 and BMP9), these
mature adipocytes with dedifferentiation potentials, also referred
to as dedifferentiated fat cells (DFATCs), can spontaneously un-
dergo mesenchymal-endothelial transition and differentiate into
endothelial cells that actively participate in neovascularization
Figure 1. Adipocyte and Endothelial Cell
Differentiation and Transdifferentiation
Reciprocal cellular switch between vascular cells
and adipocytes (ACs). Under certain circum-
stances, cells located in the vessel wall including
endothelial cells (ECs), pericytes (PCs), and
vascular smooth muscle cells (VSMCs) can un-
dergo differentiation to become BAT and WAT
adipocytes. Inversely, mature white adipocytes
can dedifferentiate into DFATCs that give rise to
ECs and VSMCs, which actively participate in
adipose angiogenesis. Mature adipocytes also
exhibit multilineage potential to differentiate into
multiple mesenchymal lineages including bone,
cartilage, cardiomyocytes, and skeletal muscles.
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tiate into smooth muscle cells (Sakuma et al., 2009).
The interplay and cell-type switch between adipocytes and
vascular cells are mediated by multiple signaling systems that
determine cell proliferation and differentiation. For example,
genetically constitutive activation of the PDGFR-b signaling
system promotes pericyte proliferation but inhibits its differenti-
ation toward WAT adipocytes (Olson and Soriano, 2011).
PPAR-g has also been reported to coordinate preadipocyte dif-
ferentiation and angiogenesis in PPAR-g-activator-treated
mouse models (Gealekman et al., 2008). Vascular endothelial
growth factor B (VEGF-B), originally described as an angiogenic
factor, has recently been described as a factor that mediates
fatty acid transport and insulin sensitivity (Hagberg et al.,
2012). These studies show that multiple signaling systems are
involved in the modulation of adipocyte-endothelial cell interac-
tion and their functions.
Angiogenic Driving Force and Reciprocal Interactions
between Various Cell Types
Both intrinsic adipocyte and constant microenvironmental
alterations in various adipose tissues determine dynamic
changes of the angiogenic driving force. For example, during
the early stage of embryonic development, the formation of the
initial adipose niche by stem cell-derived preadipocytes is
spatiotemporally coupled to the switch of an angiogenic pheno-
type (Cao, 2007; Crandall et al., 1997). An early study showed
that differentiation from preadipocytes to mature adipocytes
was concomitantly linked to elevated production of angiogenic
factors that induces robust angiogenic responses (Castellot
et al., 1982). Adipose-derived stem cells produce high levels of
a range of proangiogenic factors, including fibroblast growth
factor 2 (FGF-2), VEGF, hepatocyte growth factor (HGF), and
PDGFs (Lee et al., 2012), and an adipocyte differentiation-
inducer, PPARg activator, can further boost expression levels
of VEGF, VEGF-B, and angiopoietin-like factor-4 (Gealekman
et al., 2008) (Figure 2). Ingrowth of blood vessels in adipose tis-
sues permits and facilitates reciprocal interaction betweenCell Metabolism 1adipocytes and endothelial cells. Preadi-
pocytes induce and guide endothelial
cell migration (Borges et al., 2007) via
FGF- and VEGF-dependent pathways,
whereas the VEGF-triggered signaling
pathway in endothelial cells promotespreadipocyte differentiation via a paracrine mechanism (Fuku-
mura et al., 2003).
The oxygen tension in the adipose is determined by several
factors, including vascular density and function, metabolic
status, and the composition of other cell types. However, it is
unclear whether this is a cause or a consequence of obesity-
associated metabolic disorders. Enlargement of adipocyte sizes
would increase the intercapillary distance, resulting in relatively
decreased blood perfusion to each adipocyte and a global
decrease of adipose oxygen tension. Thus, the vascular density
per adipocyte in a rigid field is relatively reduced. However,
enlargement of adipocyte sizes may also result in decreased
metabolic demands, and adipocytes may not necessarily suffer
from tissue hypoxia. It is also highly plausible that the vessel
growth rate and rapid expansion of adipocyte sizes in obese in-
dividuals occur in an uncoordinated manner, leading to insuffi-
cient angiogenesis and tissue hypoxia. Adipose tissue hypoxia
has consistently been reported in various animal models of
obesity, including genetically obese ob/ob and db/db mice,
obese Zucker rats, and high-fat diet (HFD)-fed mice (Goossens
and Blaak, 2012; Ye et al., 2007). Consequently, expression
levels of certain hypoxia-inducible genes, such as hypoxia-
inducible factor-1 alpha (HIF-1a) and glucose transporter, are
elevated in obese WAT relative to those in lean mice (Goossens
and Blaak, 2012). In response to hypoxia, white and brown adi-
pocytes may employ different mechanisms to induce targeted
gene expression. For example, HIF-1a in white adipocytes is
required for the induction of hypoxia-targeted gene expression,
but it is not essential for hypoxia-induced targeted gene ex-
pression in brown adipocytes (Pino et al., 2012). VEGF is a direct
transcriptional target of HIF-1a. Thus, the hypoxia-HIF-1a-VEGF
axis may serve as an angiogenic driving force of rapidly expand-
ing WAT tissues. Indeed, enforced expression of VEGF in adi-
pose tissues produced a hypervascularized phenotype (Elias
et al., 2012; Sun et al., 2012). Additionally, adipose tissue hypox-
ia may potentially upregulate expression levels of endothelial
VEGFR2, as seen in other tissues (Brogi et al., 1996), which
transduces the VEGF-triggered angiogenic signaling. Notably,8, October 1, 2013 ª2013 Elsevier Inc. 479
Figure 2. Reciprocal Interplay between Vascular and Adipocyte Compartment
Cells in the vessel wall, i.e., endothelial cells (ECs), pericytes (PCs), and vascular smoothmuscle cells (VSMCs), may produce various soluble and insoluble factors
that crosstalk to adipocytes (ACs) via a paracrine regulatory mechanism. Conversely, adipocytes produce a range of angiogenic factors, cytokines, and adi-
pokines that collectively modulate vascular growth, regression, vascular survival, vascular remodeling, and blood perfusion. In the adipose microenvironment,
other cell types including inflammatory cells (IFCs) and mesenchymal stromal cells (MSCs) also actively participate in the complex regulation of vascular
functions. In expanding obese adipose tissues, hypoxia may potentially facilitate the interaction between endothelial cells and adipocytes by elevating the
production of hypoxia-regulated angiogenic factors such as VEGF.
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in the adipose tissue. For example, in a genetic mouse model,
constitutive overexpression of an active form HIF-1a in adipose
tissue fails to induce a proangiogenic response but unexpect-
edly triggers adipose tissue fibrosis and local inflammation (Hal-
berg et al., 2009). Consistent with this notion, levels of VEGF, one
of the classical targets of HIF-1a, were not elevated. Mechanis-
tically, it is unclear why VEGF levels were not elevated in consti-
tutive HIF-1a expression. One possibility would be that the dele-
tion mutant HIF-1a was unable to induce and to sustain VEGF
expression in adipocytes. Unlike other cell types, adipocytes
may employ other HIF-1a-independent mechanisms to induce
VEGF expression and angiogenesis. These speculations and
discrepant findings warrant further mechanistic investigations.
Obese WAT exhibits chronic inflammation by infiltrating mac-
rophages, neutrophils, and immune cells, which, together with
adipocytes and stromal vascular cells, produce various inflam-
matory cytokines (Donath and Shoelson, 2011). Noticeably,
neovascularization in adipose tissues could further intensify the
inflammatory process by increasing the infiltration of inflamma-
tory cells. Adipose tissue hypoxia in obesity is not only the pri-
mary driving force of angiogenesis, but also an essential trigger
for initiating chronic inflammation (Trayhurn, 2013). Specific
expression of VEGF in adipose tissues improves tissue hypoxia
and suppresses fibrosis and local inflammation (Sun et al., 2012).
It is unclear why VEGF-enhanced adipose angiogenesis resulted
in anti-inflammatory rather than proinflammatory responses.
Analysis of the expression of inflammatory factors demonstrated
that levels of interleukin 6 (IL-6) and tumor necrosis factor alpha
(TNF-a) are significantly downregulated. Insufficient angiogen-
esis in response to adipose tissue hypoxia has also been sug-
gested to activate the chronic inflammatory process (Ye,480 Cell Metabolism 18, October 1, 2013 ª2013 Elsevier Inc.2009). In support of this notion, an independent study shows
that enforced expression of VEGF in the adipose tissue leads
to the accumulation of M2 anti-inflammatory and fewer M1
proinflammatory macrophages (Elias et al., 2012). Inversely,
deletion of VEGF in adipose tissues in mice also resulted in
reduced inflammation with increased adipose hypoxia (Sung
et al., 2013).
Similar to inflammatory cells, adipose mesenchymal cells pro-
duce an array of angiogenic factors and cytokines, including
VEGF, PDGF, FGF, HGF, and TGF-b (Cao, 2007) (Figure 2). In
addition to angiogenic factors and proangiogenic cytokines,
adipose-tissue-derived hormones, adipokines, play a crucial
role in the modulation of adipose angiogenesis. It is recognized
that adipose tissues produce more than 600 bioactive factors
that are collectively termed adipokines. These adipokines posi-
tively and negatively modulate adipose angiogenesis, vascular
homeostasis, and vascular integrity. For example, whereas lep-
tin induces angiogenesis, vascular fenestration, and vascular
remodeling (Bouloumie´ et al., 1998; Cao et al., 2001; Sierra-Hon-
igmann et al., 1998), adiponectin may inhibit angiogenesis
(Bra˚kenhielm et al., 2004b; Man et al., 2010). Adipose-derived
resistin, chemerin, omentin, vaspin, and visfatin are all able to
modulate angiogenesis (Bozaoglu et al., 2010; Kim et al.,
2007b; Kukla et al., 2011; Mu et al., 2006; Northcott et al.,
2012). It appears that some of these proadipokines can synergis-
tically stimulate angiogenesis with known angiogenic factors;
examples include leptin plus VEGF and leptin plus FGF-2 (Cao
et al., 2001).
Several known endogenous angiogenesis inhibitors, such
as adiponectin, thrombospondin, and soluble VEGF receptors
(sVEGFRs), are downregulated in angiogenic adipose tissues
(Xue et al., 2009). Intriguingly, hypoxia potently downregulates
Figure 3. Angiogenic Functions in Adipose
Tissues
Immunohistochemical CD31 staining of mouse
inguinal WAT and interscapular BAT demonstrates
that both adipose depots contain high microvas-
cular density. In particular, BAT is the probably the
most vascularized tissue in the body. Microvas-
cular networks in each of these adipose tissues
may display distinct functions. In WAT, angiogen-
esis promotes energy storage by enhancing lipid
transport and deposition and may modulate
adipocyte-related endocrine, paracrine, and au-
tocrine functions. In contrast, the same angiogenic
process augments lipolysis in metabolically active
BAT. The angiogenic process is tightly regulated
by various angiogenic and vascular remodeling
factors, which coordinately control vascular
growth. For example, adipocyte- and non-
adipocyte-derived VEGF could build up an
‘‘angiogenic gradient’’ that guides vascular
sprouting by formation of endothelial cell tips. This
process is coordinately regulated by other
signaling systems including the PDGF-BB-
PDGFR-b signaling in pericytes and the Dll4-Notch
signaling to prevent excessive vascular sprouting
and undirected growth.
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derived growth factor (PEDF), and sVEGFR1 (Bienes-Martı´nez
et al., 2012; Famulla et al., 2011; Shitaye et al., 2010),
possibly leading to further acceleration of hypoxia-induced
angiogenesis. Consistent with antiangiogenic function, ge-
netic deletion of thrombospndin-2 in adipose tissue led to
accelerated adipogenesis and hypersusceptibility of obesity
development (Shitaye et al., 2010). These findings suggest
that upregulation of proangiogenic factors and downregulation
of endogenous angiogenesis inhibitors may be both necessary
and sufficient for switching on an adipose angiogenic phe-
notype.Cell Metabolism 1Vascular Functions in White and
Brown Adipose Tissues
Adipose tissues, especially BAT, are
probably the most vascularized tissues
in the body, and the adipose vessel
density is usually higher than those found
in pathological tissues (Lim et al., 2012;
Xue et al., 2010) (Figure 3). The adipose
vasculature has multiple functions in the
modulation of adipocyte functions (Cao,
2010). These include (1) providing nutri-
ents and oxygen essential for the
maintenance of adipocyte survival and
functions; (2) removing metabolic prod-
ucts from adipose tissue; (3) transporting
nonadipose-tissue-derived growth fac-
tors, cytokines, and hormones for mo-
dulating adipocyte functions and growth;
(4) transporting adipose-tissue-derived
growth factors, adipokines, and cytokines
for removal of tissues globally regulating
physiological functions via the endocrine
mechanism; (5) paracrine and juxtacrineregulation of adipocyte functions through the production of
various factors and cytokines from vascular cells; (6) supplying
adipocyte vessel wall stem and precursor cells that can
eventually differentiate into mature adipocytes; (7) supplying
circulating stem cells from nonadipose tissues to adipose
tissues; (8) preparation of adipose niche formation during
embryonic development by the vasculature; (9) supplying other
cell types such as inflammatory cells that secondarily affect
adipocyte function; and (10) alteration of the adipose micro-
environment such as hypoxia and acidosis, which control adipo-
cyte function, preadipocyte differentiation, and adipose tissue
mass.8, October 1, 2013 ª2013 Elsevier Inc. 481
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mentioned common functions, the ultimately functional con-
sequence is dependent on the metabolic status of adipocytes.
In WAT, switching to an angiogenic phenotype would facilitate
to the process of energy deposition, resulting in adipose tissue
expansion. In expanding fat pads at the early stages of a HFD
challenge, specific expression of VEGF in WAT enhances angio-
genesis, leading to a ‘‘browning phenotype’’ of WAT (Elias et al.,
2012; Michailidou et al., 2012; Sun et al., 2012), which is benefi-
cial for the improvement of metabolism. Additionally, vascula-
tures in healthy WAT play an essential role in controlling adipo-
kine and other hormone release and transport. Similar to
microvessels in various endocrine organs, the adipose vascula-
ture contains vasculature fenestrations, which are essential for
maintaining the physiological functions of endocrine tissues
(Cao et al., 2001). In obese individuals, active adipose angiogen-
esis in WAT is likely to further promote obesity. Angiogenesis in
WAT may also control energy metabolism by modulating adipo-
cyte-associated endocrine, paracrine, and autocrine functions,
given that WAT is considered one of the largest endocrine
tissues in the body (Harwood, 2012). Alteration of vascular den-
sity and structure would result in changes in the composition and
architecture of adipocytes in relation to other cellular compo-
nents in WAT. Ultimately, angiogenesis would have a signifi-
cantly functional impact of energy metabolism through modula-
tion of adipocyte-related endocrine, paracrine, and autocrine
mechanisms. In contrast to in WAT, activation of angiogenesis
in BAT would increase the oxygen supply and thereby fuel the
process of energy consumption, leading to a lean phenotype.
Vascular Changes during Thermogenesis
BAT located in the interscapular region plays an essential role for
thermogenesis, which is crucial for the survival of small mam-
mals in cold environments (Cannon and Nedergaard, 2004). In
humans, the amount of BAT markedly deceases after the infant
stages. A large cohort analysis in adult humans using (18)F-fluo-
rodeoxyglucose positron-emission tomographic and computer
tomographic scanning shows that substantial depots of BAT
exist in the supraclavicular region, the anterior area in the neck
and thorax (Cypess et al., 2009). More importantly, the amount
BAT has been inversely correlated with body-mass index
(BMI), implying the potential role of BAT in the modulation of
adult human metabolism (Cypess et al., 2009). However, the
identity of BAT in adult humans has recently become a disputed
issue. Recent findings show that the previously described BAT
depots in adult humans are actually brown-like, also called
brown-in-white (brite)/beige, adipose tissues, which is different
from the classical BAT (Wu et al., 2012). These findings raise
an important question of the existence of BAT in humans.
However, another recent study employing a combination of
high-resolution imaging techniques, histology, and biochemical
analyses has discovered that the classical thermogenic organ
of bona fide BAT does exist in human infants (Lidell et al.,
2013). Thus, humans have two distinct types of BAT, i.e., bona
fide BAT and inducible brown-like brite/beige adipose tissues.
Cold acclimation of mice can lead to the transition of WAT into
a BAT-like adipocyte phenotype, also termed brite or beige ad-
ipocytes (Petrovic et al., 2010) (Figure 4). Brite/beige adipocytes
enrich uncoupling protein 1 (UCP1)-positive mitochondrial con-482 Cell Metabolism 18, October 1, 2013 ª2013 Elsevier Inc.tents that are essentially required for catalyzing nonshivering
thermogenesis (Heaton et al., 1978). Intriguingly, PGC-1a
potently upregulates VEGF expression and angiogenesis
in vitro and in vivo through a noncanonical pathway, i.e., the
HIF-independent hypoxia-response pathway (Arany et al.,
2008). Consistent with these findings, VEGF expression levels
in the whole inguinal adipose tissue are elevated through a hyp-
oxia-independent but possibly PGC-1a-dependent mechanism
(Xue et al., 2009). The VEGF-VEGFR2 signaling system is primar-
ily responsible for the initiation of adipose angiogenesis in the
brite/beige adipose tissue given that VEGFR2 blockade, but
not VEGFR1 blockade, could abolish the cold-induced angio-
genesis (Xue et al., 2009). Endogenous angiogenesis inhibitors
such as thrombospondin are simultaneously downregulated,
tipping the balance toward angiogenic stimuli (Figure 4). It is
noteworthy that the cold-induced angiogenic response occurs
only transiently and reaches a higher steady-state level after
persistent exposure to cold (Lim et al., 2012; Xue et al., 2009).
Angiogenesis is switched off by decreasing VEGF levels and
by increasing production of an sVEGFR1 that negatively regu-
lates VEGF function (Xue et al., 2009). Another regulatory mech-
anism may involve sympathetic release of neuropeptide Y (NPY)
during cold-induced chronic stress, which stimulates adipose
angiogenesis via activation of NPY-Y2 receptors (Ekstrand
et al., 2003; Kuo et al., 2007).
Exposure of adult humans to low temperatures also leads to
activation of BAT and thermogenesis-associated metabolism
(vanMarken Lichtenbelt et al., 2009). It is reasonably speculated,
although not currently proved, that cold activation of BAT
concomitantly induces angiogenesis in human BAT tissues. If
so, vascular functions under this circumstance warrant future
investigation. A brite/beige phenotype is also observed in several
mouse genetic models. For example, specific overexpression of
forkhead box protein C2 (FOXC2) in the adipose tissue produces
a brown-like phenotype and switches on an adipose angiogenic
phenotype (Cederberg et al., 2001; Xue et al., 2008). Mechanis-
tically, FOXC2 directly targets the angiopoietin-2 (Ang-2) pro-
moter to trigger an angiogenic response, and the elevated level
of Ang-2 results in marked vascular remodeling by ablating peri-
vascular cell coverage (Xue et al., 2008). The FOXC2-associated
angiogenic phenotype can be completely prevented by specific
inhibition of the Ang-2 signaling pathway. Thus, activation of BAT
and the brite/beige transition under various experimental models
may employ different angiogenesis mechanisms.
Vascular Functions in Modulation of Insulin Sensitivity
The initial evidence of adipose vasculatures in modulation of
insulin sensitivity was obtained from genetic and HFD-fed obese
mousemodels that received treatment of a generic angiogenesis
inhibitor, TNP-470, which is relatively specific for endothelial
cells (Bra˚kenhielm et al., 2004a; Rupnick et al., 2002) (Figure 5).
More recently, several published works from independent
groups provide compelling evidence supporting the crucial roles
of adipose angiogenesis in the modulation of insulin sensitivity
(Elias et al., 2012; Lu et al., 2012; Michailidou et al., 2012; Sun
et al., 2012; Sung et al., 2013). In TNP-470-treated obese
mice, reduction of adipose vascular density was correlated
with improved insulin sensitivity (Bra˚kenhielm et al., 2004b).
However, the TNP-470-improved insulin sensitivity might be
Figure 4. Cold- and Adrenergic-Activation-
Induced Adipose and Vascular Plasticity
(A) Exposure to cold- and drug-induced adrenergic
activation can lead to activation of BAT that
executes nonshivering thermogenesis function via
an UCP1-dependent pathway. Intriguingly, acti-
vation of thermogenic metabolism in BAT triggers
a robust and VEGF-dependent angiogenic
response. Concomitant to upregulation of VEGF
and other angiogenic factors, endogenous angio-
genesis inhibitors including thrombospodin (TSP)
and a sVEGFR are downregulated to further ensure
robust activation of angiogenesis. In rodents and
probably other hibernated animals, cold exposure
and drug-induced adrenergic activation induces a
BAT-like phenotype in WAT (brite/beige), which
displays similar thermogenic functions as BAT.
Again, active angiogenesis occurs during the brite/
beige transition.
(B) As VEGF is primarily involved in stimulation of
angiogenesis during BAT activation and brite/
beige transition, adrenergic activation of VEGF
expression has been studied, and the underlying
mechanism involves hypoxia-independent activa-
tion of the vegf promoter by PGC-1a. However,
hypoxia-dependent angiogenesis cannot be
completely excluded.
Cell Metabolism
Reviewattributable to its nonantiangiogenic activity because TNP-470
has neurotoxicity effects (Bhargava et al., 1999; Kudelka et al.,
1997). A recent study shows that TNP-470 significantly inhibited
food intake and increased energy expenditure, leading to
reduced body-weight gain (White et al., 2012). Thus, it is highly
plausible that the previously observed TNP-470-induced amelio-
ration of insulin resistance is due to the suppression of foodCell Metabolism 1intake rather than adipose angiogenesis.
The mechanism underlying TNP-470-
modulated energy balance may involve a
novel regulatory signaling pathway by
which the adipose vasculature acts
centrally to regulate energy balance, as
seen with an adipose-endothelium-
specific proapototic peptide (Kim et al.,
2010; Kim et al., 2007c). Despite signifi-
cant reduction of body fat in HFD-fed
obese mice, White et al. (2012) showed
that TNP-470-treated mice exhibited
glucose intolerance, raising the possibility
that other tissues such as muscle tissues
also significantly contribute to glucose
intolerance.
Subsequent studies of vascular func-
tions in the modulation of insulin sensi-
tivity were mostly focused on VEGF, a
bona fide endothelial growth factor,
owing to its relatively specific targets on
vascular endothelial cells. VEGF modu-
lates insulin activity by regulating its
production in pancreatic islets and its
sensitivity in peripheral tissues such as
adipose andmuscle tissues. An important
clue for how VEGF maintains these
vascular features was achieved by gener-ating a genetic mouse strain that carries specific VEGF-A dele-
tion in b cells (RIP-Cre:Vegffl/fl). As expected, vascular density
and fenestrations were markedly reduced in RIP-Cre:Vegffl/fl
mice, as well as in mice with pancreatic-specific deletion of
VEGF (PDX1-Cre:Vegf fl/fl) (Brissova et al., 2006; Iwashita et al.,
2007; Watada, 2010). Interestingly, despite reduced insulin
secretion in the islets, these mice do not seem to show obvious8, October 1, 2013 ª2013 Elsevier Inc. 483
Figure 5. Antiobesity Therapy by Targeting
Angiogenesis
In WAT, inhibition of angiogenesis may provide a
new therapeutic option for the treatment of obesity
and diabetic retinopathy. In contrast, delivery of
proangiogenic factors to metabolically active BAT
may further accelerate metabolism, leading to a
lean phenotype and improved insulin sensitivity.
Stimulation of angiogenesis is also beneficial for
the treatment of nonhealing diabetic ulcers.
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Watada, 2010). VEGF has also been reported to acts as a sur-
vival factor for b cells through maintenance of vascular numbers
and integrity (Xiao et al., 2013).
The role of adipose VEGF in obesity and insulin sensitivity was
also investigated using gain-of-function and loss-of-function
genetic mouse models. In one study, temporal repression of
systemic VEGF expression leads to a lean phenotype and resis-
tance to diet-induced obesity owing to development of BAT-like
adipocytes in WAT (Lu et al., 2012). In contrast, several other
studies show that overexpression, but not repression, of VEGF
in adipose tissues protects against diet-induced obesity and in-
sulin resistance (Elias et al., 2012; Sun et al., 2012; Sung et al.,
2013), although the activation of the BAT-like phenotype remains
a significant part of the discrepancy. Sung et al. (2013) show that
specific deletion or overexpression of VEGF in adipose tissues
results in alterations of the adipose microenvironment and tissue
hypoxia. In adipose VEGF-deleted mice, reduction of vascular
density leads to hypoxia, apoptosis, inflammation, and meta-
bolic defects in response to HFD. Inversely, high VEGF levels
improve hypoxia and compromise obesity-related metabolic
disorders. Although the discrepancy around VEGF in controlling
metabolism remains unresolved, it highlights complex mecha-
nisms that underlie the vasculature in the modulation of adipo-484 Cell Metabolism 18, October 1, 2013 ª2013 Elsevier Inc.cyte functions. A recent study showed
that VEGF-B, a VEGF family member
that exclusively binds to VEGFR1 (Cao,
2009), modulates endothelial fatty acid
uptake and transport in muscular tissues
(Hagberg et al., 2010). Moreover, genetic
deletion of the vegfb gene and pharmaco-
logical inhibition of VEGF-B triggered
signaling in diabetic mice that restored
insulin sensitivity and glucose tolerance
(Hagberg et al., 2012). In addition to
the VEGF family, a genetically modified
angiopoietin-1 variant, a more potent
version of its native form, can improve in-
sulin sensitivity by stimulation of adipose
and muscle angiogenesis (Jung et al.,
2012; Sung et al., 2009).
Although these preclinical findings are
seemingly contradictory in gain-of-func-
tion and loss-of-function experimental
settings, careful analysis of all data by
taking into consideration the different
experimental conditions reveals consis-
tent rather than contradictory conclusionsregarding the VEGF paradox. It appears that the ultimate conse-
quences of VEGF-modulated angiogenesis in controlling adi-
pose tissue functions are context dependent (Sun et al., 2012).
In expanding fat pads at the early stages of a HFD challenge,
specific expression of VEGF in WAT enhances angiogenesis,
leading to a ‘‘browning phenotype’’ of WAT (Sun et al., 2012).
Interestingly, The VEGF-overexpressing adipose tissues show
markedly elevated expression levels of UCP1 and PGC-1a,
two browning adipose markers in brite/beige adipose tissues
(Kajimura et al., 2010). Additionally, VEGF-induced browning ad-
ipose tissues exhibit a smaller average size of adipocytes,
improvement of hypoxia, reduced fibrosis, and decreased
inflammation (Sun et al., 2012; Sung et al., 2013). Importantly,
overexpression of VEGF in adipose tissues significantly im-
proves glucose tolerance, insulin sensitivity, and other metabolic
abnormalities in HFD-fed mice. Consistent with these findings,
genetic overexpression of aP2-driven VEGF in WAT and BAT
markedly increased microvessel density that protects these tis-
sues from hypoxia andHFD-induced obesity andmetabolic abo-
normalities (Elias et al., 2012). The overall conclusions from this
study (Elias et al., 2012) are in general agreement with two other
studies (Sun et al., 2012; Sung et al., 2013) that adipose VEGF
expression protects mice from HFD-induced obesity, glucose
intolerance, insulin resistance, and adipose tissue inflammation.
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adipose tissues produced an opposing phenotype. Adipose tis-
sues in the VEGF deletion mice show low vascular density, high
degrees of tissue hypoxia, elevated apoptosis of adipocytes,
inflammation, and metabolic defects on a HFD (Sung et al.,
2013). These findings demonstrate that stimulation of angiogen-
esis in expanding adipose tissue is beneficially protective from
development of metabolic disorders and insulin resistance
(Sung et al., 2013).
In another study, genetic repression of VEGF expression in
various tissues results in a similar protective effect against
HFD-induced obesity (Lu et al., 2012), as seen in adipose-tis-
sue-specific VEGF overexpression expression models (Elias
et al., 2012; Sun et al., 2012; Sung et al., 2013). Intriguingly, sys-
temic VEGF repression also produced a browning adipose
phenotype with upregulation of UCP1 and cell-death-inducing
DNA fragmentation factor-a-like effector A (CIDEA) (Lu et al.,
2012). Although molecular mechanisms underlying systemic
repression of VEGF against HFD-induced obesity remain un-
known, it is speculated that complex signaling systems might
be involved in global regulation of metabolism, in association
with vascular changes in various tissues and organs. Systemic
VEGF repression may alter vascular numbers and structures in
nonadipose tissues and organs, which subsequently modulate
global metabolism in the body. For example, it is known that
VEGF under physiological conditions is a maintenance factor
for vascular homeostasis and systemic inhibition of the VEGF-
VEGFR2 signaling pathway in adult mice leads tomarked regres-
sion of microvascular networks in various tissues (Kamba et al.,
2006; Yang et al., 2013). In particular, microvasculatures in endo-
crine glands are exceptionally susceptible VEGF blockades. In
the thyroid, pancreatic islets, and adrenal glands, for example,
a more than 50% reduction of vascular density has been
observed in these healthy tissues in response to anti-VEGF treat-
ment (Kamba et al., 2006; Yang et al., 2013). Although functional
impacts of VEGF inhibition on endocrine functions need to be
proven in this pharmacological-intervention mouse model, sus-
tained VEGF suppression as in the case of a genetically repres-
sive mouse model would probably affect global metabolism and
insulin sensitivity. Thus, nonadipose tissue effects of VEGF-
associated vascular regression may significantly modulate
metabolism and glucose tolerance. Taken together, these
various findings from different laboratories may not necessarily
contradict each other or the role of VEGF in the modulation of
adipose tissue functions, metabolism, and insulin sensitivity
manifested in a spatiotemporal and context-dependent manner.
Several preliminary studies on human subjects suggest a
possible correlation between adipose VEGF levels and insulin
sensitivity. In one study, adipose levels of VEGF, VEGF-B,
VEGF-C, and VEGF-D are negatively correlated with the devel-
opment of insulin resistance in human obese patients (Tinahones
et al., 2009). Other human patient data show that angiogenesis in
subcutaneous adipose tissues is associated with the develop-
ment of insulin resistance by enhancing lipid storage (Kim
et al., 2007a). Analysis of a relatively small group of healthy
young males implies the existence of a positive correlation be-
tween circulating VEGF levels and BMI, which is disassociated
from insulin sensitivity (Loebig et al., 2010). It is noteworthy
that unlike preclinical research, clinical studies with human sam-ples, particularly in small-cohort populations, are complex, and
data can be influenced by other factors such as lifestyle, smok-
ing, alcohol intake, and physical exercise.
Therapeutic Challenges of Targeting Adipose
Vasculature
As discussed above, angiogenesis in BAT and WAT may
produce opposing effects in controlling energy expenditure
and lipid deposition. Could the proangiogenic or antiangiogenic
concept be translated for the treatment of obesity and its related
metabolic disorders? At the time of writing, therapeutic angio-
genesis for treatment of obesity andmetabolic diseases remains
a paradoxically disputed issue, and there are limited data in the
literature to conclusively support either option (Figure 5). Early
studies using genetic and HFD-induced obese models in mice
showed that delivery of generic angiogenesis inhibitors,
including TNP-470 and angiostatin, markedly prevents obesity
development (Bra˚kenhielm et al., 2004a; Rupnick et al., 2002).
These findings have been validated by several subsequent
studies (Kim et al., 2007c; White et al., 2012). In these low-meta-
bolic obese mice, systemic treatment with broad-spectrum
angiogenesis inhibitors suppresses adipose angiogenesis in
variousWAT depots, which is, in part, responsible for the antiob-
ese effect. TNP-470 may target a broad-spectrum of cell types
other than endothelial cells (Kudelka et al., 1997), and these
non-vascular-related effects might also contribute to its antiob-
ese activity. One of the intriguing findings of these studies is
that TNP-470-treated obese mice demonstrate improved insulin
sensitivity and blood lipid profiles (Bra˚kenhielm et al., 2004a). In
clinical scenarios, the reduction of existing adipose tissue mass
in obese individuals should be considered, and this may employ
a rather different vasculature-related mechanism such as selec-
tive regression of adipose blood vessels. To achieve this goal,
molecular players that control vascular survival signals in WAT
should be identified and defined as potential therapeutic targets.
Owing to their crucial roles in the regulation of angiogenesis,
targeting VEGF-induced angiogenic signaling pathways for
antiobese implications has become a focused theme in most
studies. Despite the availability of various VEGF inhibitors, there
is only limited published data to show the impact of anti-VEGF
agents on adipose tissue growth. Specific inhibition of VEGFR2,
but not VEGFR1, results in restriction of adipose tissue expan-
sion, largely due to antiangiogenesis, in HFD-fed mice
(Fukumura et al., 2003; Tam et al., 2009). Treatment with
VEGFR2-specific blockade in HFD-fed mice did not result in
significant body-weight changes during the first 5–6 weeks of
diet-induced obesity (Tam et al., 2009). However, prolonged
treatment with VEGFR blockade significantly decreased the
body-weight gain compared with the HFD-fed control group.
The VEGFR2-blockade-treated group had significantly lower
food intake relative to the control group, and the VEGFR2-
blockade-induced body-weight loss and food-intake reduction
was reversible after cessation of treatment (Tam et al., 2009).
Most other data were obtained from VEGF genetic models us-
ing the gain-of-function and loss-of-function approaches. As
discussed in the section of insulin sensitivity, the findings around
VEGF-related obesity and metabolism exhibit spatiotemporal
and context-dependent manner. Although some genetic studies
are consistent with the pharmacological intervention of theCell Metabolism 18, October 1, 2013 ª2013 Elsevier Inc. 485
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type in VEGF-deleted adipose tissues (Lu et al., 2012; Sung
et al., 2013), others show that overexpression, but not repres-
sion, of VEGF protects mice from obese development (Elias
et al., 2012; Sun et al., 2012). In both adipose VEGF overexpres-
sion and repression genetic models, activation of a BAT-like
phenotype has been reported (Lu et al., 2012; Sun et al., 2012).
Although the discrepancy of these findings warrants future
clarification, these data, at least, demonstrate that targeting
VEGF for treatment of obesity is not a straightforward approach.
Careful examinations of these various findings show that anti-
VEGF treatment of established adipose tissues should be sepa-
rated from those of expanding adipose tissues at the early stage
of obesity. Systemic anti-VEGF treatment of expanding adipose
tissues at the early stage of obesity results in increased adipo-
cyte sizes and glucose intolerance (Sun et al., 2012). Paradoxi-
cally, delivery of the same VEGF blockade to established ob/
ob mice resulted in increased adipocyte death, weight loss,
and improvement of glucose tolerance (Sun et al., 2012). It
should be emphasized that systemic treatment with VEGF
blockade may be likely to affect the pre-existing vasculatures
in various tissues and organs as reported in nonobese mice
(Kamba et al., 2006; Yang et al., 2013).
Thus, the ultimate metabolic alterations of systemic pharma-
cological intervention reflect both adipose and nonadipose
vascular changes. Interestingly, systemic delivery of a VEGF
blockade to mice at the early stage of obesity only results in
vascular changes in the adipose tissue, but not other tissues
(Sun et al., 2012). Perhaps this is a dose-related phenomenon,
given that angiogenic vessels in the adipose tissue would be
more sensitive to anti-VEGF treatment than quiescent vascula-
tures in other tissues. Increases of anti-VEGF dosages may be
likely to affect other vasculatures, owing to the fact that VEGF
is a bona fide maintenance factor for vascular homeostasis in
various tissues and organs (Kamba et al., 2006; Yang et al.,
2013). In contrast to the systemic model, local deletion of the
Vegf gene in the adipose tissue increases tissue hypoxia, inflam-
mation, and metabolic defects including glucose intolerance in
association with reduction of vascularity (Sung et al., 2013).
The systemic impact of anti-VEGF agents on modulation of
body weight, BMI, metabolism, glucose tolerance, and insulin
sensitivity can be learnt from various cancer patients who
receive anti-VEGF drugs, such as bevacizumab (Hurwitz et al.,
2004). However, it seems to be difficult to obtain any conclusive
results from human patient trials using bevacizumab and other
VEGF inhibitor owing to several reasons: 1) given that anti-
angiogenic monotherapy does not, in most human cancer types,
produce beneficial effects, anti-VEGF drugs are, in most cases,
codelivered to patients together with chemotherapeutics, which
significantly suppress appetite, vomiting, hepatotoxicity, gastro-
intestinal (GI) functions including stomatitis, mucositis, and
diarrhea, and hematological toxicity (Perry, 1992). These chemo-
therapy-induced broad and GI-associated side effects signifi-
cantly reduce body weight; (2) in almost all FDA-approved
antiangiogenic trials, cancer patients with advanced and meta-
static diseases are the primarily subjects for clinical trials.
Patients with advanced malignant diseases often suffer from
cachexia as a waste syndrome and their food-intake is minimal;
and (3) anti-VEGF monotherapy can also significantly affects GI486 Cell Metabolism 18, October 1, 2013 ª2013 Elsevier Inc.tract functions (Tol et al., 2008). Thus, it is difficult to obtain
conclusive data from these patients who receive antiangiogenic
therapy. Unless chemotherapy is removed, food intake is
accurately measured, metabolism is standardized, and systemic
disease is well controlled, it would be difficult to speculate the
body-weight outcome of anti-VEGF drugs in cancer patients.
HIF-1a in adipose tissue is another attractive target given that
HIF-1a-induced fibrotic response has been linked to hypoxia-
associated metabolic dysfunction in adipose tissues (Halberg
et al., 2009). In support of this view, treatment of HFD-fed mice
with a HIF-1a selective inhibitor, PX-478, effectively inhibits
HFD-induced HIF-1a activation (Sun et al., 2013). Interestingly,
inhibition of HIF-1a selectively reduces body-weight gain in
HFD-fed mice, but not in normal-chow-fed mice. The anti-HIF-
1a-treated mice show increased energy expenditure and
improvement of HFD-induced metabolic abnormalities, which
are well correlated with reduced adipose fibrosis and inflamma-
tion. Genetic inhibition of endogenous HIF-1a in adipose tissues
also produced similar metabolic improvements in HFD-fed mice
(Sun et al., 2013). Thus, pharmacological targeting HIF-1a in the
adipose tissue provides an attractive approach for treatment of
obesity and metabolic disorders through possible conceivable
mechanisms of inhibition of adipose fibrosis and inflammation.
A challenging issue with this approach is how anti-HIF-1a agents
are specifically delivered to the adipose tissues without interfer-
ence with its physiological functions in other tissues.
Given differential functions of the adipose vasculature in
BAT and WAT, it is reasonably to speculate that local delivery
of proangiogenic factors in metabolically active BAT would be
beneficial as an antiobese therapy. Conversely, selective
inhibition of angiogenesis in WAT would restrict energy storage
and lead to a similar antiobese effect (Figure 5). The paradoxical
view of angiogenesis-based therapy can also be extended to
obesity- and diabetes-associated complications. For example,
the type 2 diabetes-associated nonhealing foot ulcers often
seen in obese patients lack sufficient proangiogenic signals
to induce neovascularization, resulting in delayed wound heal-
ing. In this case, local delivery of proangiogenic factors such
as PDGF-BB to the ulcer bed considerably improves wound
healing (Mulder et al., 2009). On the contrary, inhibition of retinal
angiogenesis and vascular leakiness in patients with diabetic
macular edema has also been demonstrated as an effective
approach for the improvement of visual acuity and for
decreasing the risk of diabetic retinopathy progression (Smiddy,
2012). Thus, opposing angiogenesis principles, depending on
the mechanisms of pathological angiogenesis, may be applied
for the treatment of these obesity- and diabetes-related clinical
complications.
Conclusion
Accumulating preclinical data show the intimate interplay
between adipocyte and vascular compartments, which are
reciprocally dependent on each other for determining energy
expenditure or storage. Blood vessels interact with adipocytes
at different levels to modulate the adipose microenvironment
that is constantly altered throughout the entire lifetime. In
response to metabolic changes, blood vessels undergo remod-
eling, growth, or regression to justify optimal levels of oxygen
perfusion, adipocyte survival signals, supply of essential
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Reviewnutrients, and removal of metabolic products, which collectively
control adipose tissue functions. At the cellular level, adipocytes
and cells in the vessel wall possess stem cell features that allow
them to reciprocally switch to opposite cell types. Differentiation
from vascular cells into adipocytes and vice versa ensures a
prompt response to metabolic changes in adipose tissues. At
the molecular level, adipocytes and vascular cells produce a
range of soluble or insoluble factors and cytokines to reciprocally
control their functions via a paracrine mechanism. Although
adipocyte-derived factors in the regulation of adipose angiogen-
esis are relatively well characterized, the paracrine mechanisms
by which endothelial cells modulate adipocyte function remain
poorly understood. Additionally, several other cell types,
including inflammatory cells and mesenchymal stromal cells,
also actively participate in the regulation of adipose angiogen-
esis and modulate adipocyte functions. Apparently, angiogen-
esis in BAT provides sufficient fuels for energy expenditure,
whereas the same angiogenic process in WAT can also promote
energy storage. Owing to these opposing functions and the
complex mechanisms that underlie interplay between vascular
cells and adipocytes, targeting angiogenesis for treatment of
obesity and its relatedmetabolic disordersmay not be a straight-
forward approach. Future therapeutic success is dependent on
in-depth mechanistic understanding the role of angiogenesis in
the modulation of adipose tissue expansion and regression.
Despite currently limited experimental data and mechanistic un-
derstanding of adipose angiogenesis, targeting the adipose
vasculature for the treatment of obesity and metabolic disease
is an undisputed and exciting therapeutic approach that may
be beneficial for millions of obese and diabetic patients. In
fact, clinical studies have already validated the beneficial out-
comes of diabetic nonhealing ulcers andmacular edema by ther-
apeutically targeting pathological diseases.
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